Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - ipratropium bromide; salbutamol sulphate -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - ipratropium bromide monohydrate bp; salbutamol sulphate bp (micronised -

Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide (ih-pruh-troe-pee-uhm broe-mide) and albuterol sulfate (al-bue-ter-ol) inhalation  solution, usp 0.5 mg/3 mg *equivalent to 2.5 mg albuterol base read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been

Kenía - enska - Pharmacy and Poisons Board

boehringer ingelheim international gmbh binger strabe 173 55216 ingelheim am rhein germany - ipratropium bromide & salbutamol sulphate - inhalation vapour, solution - combination containing 0,5 mg ipratropium bromide… - adrenergics inhalants: adrenergics and other

Kanada - enska - Health Canada

teva canada limited - salbutamol (salbutamol sulfate); ipratropium bromide (ipratropium bromide monohydrate) - solution - 2.5mg; 0.5mg - salbutamol (salbutamol sulfate) 2.5mg; ipratropium bromide (ipratropium bromide monohydrate) 0.5mg - antimuscarinics antispasmodics

Kanada - enska - Health Canada

pharmascience inc - ipratropium bromide - solution - 125mcg - ipratropium bromide 125mcg - antimuscarinics antispasmodics

Kanada - enska - Health Canada

pharmascience inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Kanada - enska - Health Canada

pharmascience inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Kanada - enska - Health Canada

teva canada limited - ipratropium bromide; salbutamol (salbutamol sulfate) - solution - 0.5mg; 2.5mg - ipratropium bromide 0.5mg; salbutamol (salbutamol sulfate) 2.5mg - antimuscarinics antispasmodics

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram (equivalent: ipratropium bromide, qty 500 microgram) - inhalation, conventional - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for moderate asthma attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery; use during assisted ventilation with a respirator.